2026-05-17T05:52:38Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/175482024-11-29T18:56:17Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Djouder, Nabil author 2015 Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC. Mol Cell Oncol . 2015 Feb 3;2(4):e1001199. 10.1080/23723556.2014.1001199 2372-3556 Molecular & cellular oncology 27308492 http://hdl.handle.net/20.500.12105/17548 Boosting NAD(+) for the prevention and treatment of liver cancer.